Comparisons among the three groups with respect to age, MAP, hemoglobin, white blood cell count, creatinine, total bilirubin, alanine aminotransferase, myoglobulin, creatine kinase, LDH, APACHE II score, time from sting to RRT, and time from admission to RRT were performed using ANOVA. Comparisons among the three groups based on sex, hypertension, diabetes, MODS, and AKI stage were performed using the Fisher exact test. Pairwise comparisons among the three groups with respect to creatinine, total bilirubin, myoglobulin, and creatine kinase levels were performed using the Scheffe test. Pairwise comparisons among the three groups with respect to the proportion of patients with MODS were performed using the chi-square test. IHD, intermittent hemodialysis; CVVH, continuous veno-venous hemofiltration; PE, plasma exchange; MAP, mean arterial pressure; LDH, lactate dehydrogenase; APACHE II, Acute Physiology and Chronic Health Evaluation II; MODS, multiple organ dysfunction syndrome; RRT, renal replacement therapy.
^("a") Significant differences when compared to IHD group.
^(b) Significant differences when compared to CVVH group.| Comparisons among the three groups with respect to age, MAP, hemoglobin, white blood cell count, creatinine, total bilirubin, alanine aminotransferase, myoglobulin, creatine kinase, LDH, APACHE II score, time from sting to RRT, and time from admission to RRT were performed using ANOVA. Comparisons among the three groups based on sex, hypertension, diabetes, MODS, and AKI stage were performed using the Fisher exact test. Pairwise comparisons among the three groups with respect to creatinine, total bilirubin, myoglobulin, and creatine kinase levels were performed using the Scheffe test. Pairwise comparisons among the three groups with respect to the proportion of patients with MODS were performed using the chi-square test. IHD, intermittent hemodialysis; CVVH, continuous veno-venous hemofiltration; PE, plasma exchange; MAP, mean arterial pressure; LDH, lactate dehydrogenase; APACHE II, Acute Physiology and Chronic Health Evaluation II; MODS, multiple organ dysfunction syndrome; RRT, renal replacement therapy. |
| :--- |
| ${ }^{\text {a}}$ Significant differences when compared to IHD group. |
| ${ }^{\mathrm{b}}$ Significant differences when compared to CVVH group. |
Variable Total (n=81) (n=40)^(" IHD ") " CVVH
(n=27)" " CVVH + PE "_((n=14)) P Value
Age (yr) 45.5+-14.7 42.6+-15.7 49.1+-13.5 47.1+-13.1 0.19
Men/women 55/26 29/11 17/10 9/5 0.69
Hypertension 7 3 1 0.87
Diabetes 6 3 1 2 0.38
MAP (mmHg) 98.9+-16.6 96.7+-15.4 98.6 +-18.2 105.9+-15.9 0.20
Hemoglobin (g/dl) 10.07+-2.11 9.85+-1.73 10.47+-2.49 9.93 +-2.36 0.48
White blood cell count (xx10^(3)//mul) 25.87+-8.12 25.14+-8.64 26.82+-8.31 26.13+-6.34 0.71
Creatinine (mg/dl) 3.27 +-0.94 2.98+-0.76 3.60+-1.04^("a ") 3.38+-1.00 0.02
Total bilirubin (mg/dl) 4.59+-2.87 2.81 +-1.47 4.98+-2.06^(a) 8.89+-2.37^(a,b) < 0.001
Alanine aminotransferase (U/L) 729.4+-629.1 629.2+-533.1 816.4+-781.9 847.6+-546.4 0.37
Myoglobulin (U/L) 16783 +-8794 12319+-6149 19428 +-8525^("a ") 24435+-8844^("a ") < 0.001
Creatine kinase (U/L) 20080 +-10821 14700+-8121 22804+-9226^("a ") 30201+-11732^("a ") < 0.001
LDH (U/L) 5371+-2665 5039+-2642 5698+-2783 5691+-2568 0.55
APACHE II score 16.85+-2.78 16.38+-2.36 17.00+-3.33 17.93+-2.56 0.19
MODS 60/81 25/40 21/27 14//14^("a ") 0.01
Time from sting to RRT (h) 56.7+-28.4 61.1 +-24.9 57.8+-31.4 42.57+-29.5 0.11
Time from admission to RRT (h) 8.9+-4.9 8.3+-4.8 9.7+-4.6 9.2+-5.2 0.49
AKI stage (stage 2/stage 3) ( n//n ) 20/61 13/27 3/24 4/10 0.12
"Comparisons among the three groups with respect to age, MAP, hemoglobin, white blood cell count, creatinine, total bilirubin, alanine aminotransferase, myoglobulin, creatine kinase, LDH, APACHE II score, time from sting to RRT, and time from admission to RRT were performed using ANOVA. Comparisons among the three groups based on sex, hypertension, diabetes, MODS, and AKI stage were performed using the Fisher exact test. Pairwise comparisons among the three groups with respect to creatinine, total bilirubin, myoglobulin, and creatine kinase levels were performed using the Scheffe test. Pairwise comparisons among the three groups with respect to the proportion of patients with MODS were performed using the chi-square test. IHD, intermittent hemodialysis; CVVH, continuous veno-venous hemofiltration; PE, plasma exchange; MAP, mean arterial pressure; LDH, lactate dehydrogenase; APACHE II, Acute Physiology and Chronic Health Evaluation II; MODS, multiple organ dysfunction syndrome; RRT, renal replacement therapy.
^("a") Significant differences when compared to IHD group.
^(b) Significant differences when compared to CVVH group." | Variable | Total $(n=81)$ | $\stackrel{\text { IHD }}{(n=40)}$ | $\begin{aligned} & \text { CVVH } \\ & (n=27) \end{aligned}$ | $\underset{(n=14)}{\text { CVVH + PE }}$ | $P$ Value |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age (yr) | $45.5 \pm 14.7$ | $42.6 \pm 15.7$ | $49.1 \pm 13.5$ | $47.1 \pm 13.1$ | 0.19 |
| Men/women | 55/26 | 29/11 | 17/10 | 9/5 | 0.69 |
| Hypertension | 7 | | 3 | 1 | 0.87 |
| Diabetes | 6 | 3 | 1 | 2 | 0.38 |
| MAP (mmHg) | $98.9 \pm 16.6$ | $96.7 \pm 15.4$ | 98.6 $\pm 18.2$ | $105.9 \pm 15.9$ | 0.20 |
| Hemoglobin (g/dl) | $10.07 \pm 2.11$ | $9.85 \pm 1.73$ | $10.47 \pm 2.49$ | 9.93 $\pm 2.36$ | 0.48 |
| White blood cell count $\left(\times 10^{3} / \mu \mathrm{l}\right)$ | $25.87 \pm 8.12$ | $25.14 \pm 8.64$ | $26.82 \pm 8.31$ | $26.13 \pm 6.34$ | 0.71 |
| Creatinine (mg/dl) | 3.27 $\pm 0.94$ | $2.98 \pm 0.76$ | $3.60 \pm 1.04^{\text {a }}$ | $3.38 \pm 1.00$ | 0.02 |
| Total bilirubin (mg/dl) | $4.59 \pm 2.87$ | 2.81 $\pm 1.47$ | $4.98 \pm 2.06^{\mathrm{a}}$ | $8.89 \pm 2.37^{\mathrm{a}, \mathrm{b}}$ | $<0.001$ |
| Alanine aminotransferase (U/L) | $729.4 \pm 629.1$ | $629.2 \pm 533.1$ | $816.4 \pm 781.9$ | $847.6 \pm 546.4$ | 0.37 |
| Myoglobulin (U/L) | 16783 $\pm 8794$ | $12319 \pm 6149$ | 19428 $\pm 8525^{\text {a }}$ | $24435 \pm 8844^{\text {a }}$ | $<0.001$ |
| Creatine kinase (U/L) | 20080 $\pm 10821$ | $14700 \pm 8121$ | $22804 \pm 9226^{\text {a }}$ | $30201 \pm 11732^{\text {a }}$ | $<0.001$ |
| LDH (U/L) | $5371 \pm 2665$ | $5039 \pm 2642$ | $5698 \pm 2783$ | $5691 \pm 2568$ | 0.55 |
| APACHE II score | $16.85 \pm 2.78$ | $16.38 \pm 2.36$ | $17.00 \pm 3.33$ | $17.93 \pm 2.56$ | 0.19 |
| MODS | 60/81 | 25/40 | 21/27 | $14 / 14^{\text {a }}$ | 0.01 |
| Time from sting to RRT (h) | $56.7 \pm 28.4$ | 61.1 $\pm 24.9$ | $57.8 \pm 31.4$ | $42.57 \pm 29.5$ | 0.11 |
| Time from admission to RRT (h) | $8.9 \pm 4.9$ | $8.3 \pm 4.8$ | $9.7 \pm 4.6$ | $9.2 \pm 5.2$ | 0.49 |
| AKI stage (stage 2/stage 3) ( $n / n$ ) | 20/61 | 13/27 | 3/24 | 4/10 | 0.12 |
| Comparisons among the three groups with respect to age, MAP, hemoglobin, white blood cell count, creatinine, total bilirubin, alanine aminotransferase, myoglobulin, creatine kinase, LDH, APACHE II score, time from sting to RRT, and time from admission to RRT were performed using ANOVA. Comparisons among the three groups based on sex, hypertension, diabetes, MODS, and AKI stage were performed using the Fisher exact test. Pairwise comparisons among the three groups with respect to creatinine, total bilirubin, myoglobulin, and creatine kinase levels were performed using the Scheffe test. Pairwise comparisons among the three groups with respect to the proportion of patients with MODS were performed using the chi-square test. IHD, intermittent hemodialysis; CVVH, continuous veno-venous hemofiltration; PE, plasma exchange; MAP, mean arterial pressure; LDH, lactate dehydrogenase; APACHE II, Acute Physiology and Chronic Health Evaluation II; MODS, multiple organ dysfunction syndrome; RRT, renal replacement therapy. <br> ${ }^{\text {a}}$ Significant differences when compared to IHD group. <br> ${ }^{\mathrm{b}}$ Significant differences when compared to CVVH group. | | | | | |